Cellectar Biosciences (CLRB) Metrics: History & Chart

Cellectar Biosciences, Inc.(CLRB)

Biotechnology · Florham Park, NJ

$1.62-0.05 (-3.11%)

Delayed quote: Oct 6, 2026, 11:34 AM EDT

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

Florham Park, NJ

11 employees

www.cellectar.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James V. Caruso

View full financials

Third-Party DCF Estimate (FMP)	$4.39
Price Gap vs Third-Party Estimate	+162.76%

7D Total Return	0.00%
30D Total Return	0.00%
YTD Total Return	0.00%
1Y Total Return	-50.00%
3Y Total Return	-97.06%
5Y Total Return	-99.04%
10Y Total Return	-99.97%
15Y Total Return	-100.00%
20Y Total Return	-100.00%

2026	0.00%
2025	-75.00%
2024	-88.24%
2023	+61.90%
2022	-73.75%
2021	-68.25%
2020

CAGR TTM	-49.83%
CAGR 3Y	-69.12%
CAGR 5Y	-60.51%
CAGR 10Y	-55.35%
CAGR 15Y	-57.19%
CAGR 20Y	-58.10%

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

CLRB Valuation Metrics

CLRB Stock Price Metrics

CLRB Dividend Metrics

CLRB Growth Rate Metrics

CLRB Discounted Cash Flow Metrics

CLRB Returns By Period

CLRB Yearly Returns

CLRB Average Annual Returns By Period (CAGR)

CLRB Revenue Metrics

CLRB PE Ratio Metrics

CLRB PS Ratio Metrics

CLRB PB Ratio Metrics

CLRB Price to Free Cash Flow Ratio Metrics

CLRB Debt to Equity Ratio Metrics

CLRB PEG Ratio Metrics

CLRB FCF Yield

CLRB Earnings Yield

CLRB EBITDA Yield

CLRB OCF Yield

CLRB EV/EBIT Ratio Metrics

CLRB EV/EBITDA Ratio Metrics

CLRB EV/Assets Ratio Metrics

CLRB EV/Sales Ratio Metrics

CLRB Current Ratio Metrics

CLRB Quick Ratio Metrics

CLRB ROIC Metrics

CLRB Return on Assets Metrics

CLRB Return on Equity Metrics

CLRB Net Profit Margin Metrics

CLRB Gross Profit Margin Metrics

CLRB Tax Rate Metrics

PS Ratio	53099.35
PS Ratio Avg TTM	47196.93
PS Ratio Avg 3Y	8182.50
Current VS TTM Avg	+12.51%
Current VS 3Y Avg	+548.94%
Current VS 5Y Avg	+379.24%

PB Ratio	0.68
PB Ratio Avg TTM	1.31
PB Ratio Avg 3Y	2.39
Current VS TTM Avg	-47.99%
Current VS 3Y Avg	-71.55%
Current VS 5Y Avg	-46.50%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.05
Debt/Equity Ratio Avg TTM	0.10
Debt/Equity Ratio Avg 3Y	0.04
Current VS TTM Avg	-51.03%
Current VS 3Y Avg	+14.43%
Current VS 5Y Avg	+84.14%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.33
Ev/Assets Ratio Avg TTM	0.32
Ev/Assets Ratio Avg 3Y	0.90
Current VS TTM Avg	+4.44%
Current VS 3Y Avg	-63.46%
Current VS 5Y Avg	-37.75%

Ev/Sales Ratio	52963.30
Ev/Sales Ratio Avg TTM	47034.37
Ev/Sales Ratio Avg 3Y	8222.80
Current VS TTM Avg	+12.61%
Current VS 3Y Avg	+544.10%
Current VS 5Y Avg	+381.33%

Current Ratio	6.66
Current Ratio Avg TTM	3.29
Current Ratio Avg 3Y	1.87
Current VS TTM Avg	+102.53%
Current VS 3Y Avg	+256.78%
Current VS 5Y Avg	+155.18%

Quick Ratio	6.66
Quick Ratio Avg TTM	3.29
Quick Ratio Avg 3Y	1.87
Current VS TTM Avg	+102.53%
Current VS 3Y Avg	+256.78%
Current VS 5Y Avg	+155.18%

ROIC	(74.94%)
ROIC Avg 3Y	(348.38%)
ROIC Avg 5Y	(269.28%)
Current VS 3Y Avg	+78.49%
Current VS 5Y Avg	+72.17%
Current VS 10Y Avg	+58.13%

ROA	(60.93%)
ROA Avg TTM	(35.05%)
ROA Avg 3Y	(39.73%)
Current VS TTM Avg	-73.81%
Current VS 3Y Avg	-53.35%
Current VS 5Y Avg	-70.80%

ROE	(74.73%)
ROE Avg TTM	(265.31%)
ROE Avg 3Y	(309.92%)
Current VS TTM Avg	+71.83%
Current VS 3Y Avg	+75.89%
Current VS 5Y Avg	+70.31%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A